Wheeler Bio
Wheeler Bio is a privately held biologics CDMO that provides antibody-based therapeutic development and cGMP manufacturing services for emerging biopharma clients. Its ModularCMC platform delivers phase-appropriate, fixed-fee work packages compressing gene-to-clinic timelines to as few as 10 months.
- Company typePrivate
- Founded2021
- HeadquartersOklahoma City, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Wheeler Bio does
Wheeler Bio is a privately held biologics contract development and manufacturing organization (CDMO) founded in 2021 and headquartered in Oklahoma City. The company provides antibody-based therapeutic development and manufacturing services spanning cell line development, process and analytical development, cGMP drug substance and drug product manufacturing, and IND regulatory support. Its core platform, ModularCMC™, is a phase-appropriate, modular framework that combines standardized work packages with Quality-by-Design principles, aiming to compress gene-to-clinic timelines to as few as 10 months through fixed-fee work packages. The platform integrates proprietary and licensed technologies including ATUM's Leap-In Transposase system for CHO cell line development and an AI/ML clone selection model developed with the University of Oklahoma that achieves 76.2% accuracy in predicting high-yield cell lines from early-stage growth data.
The company operates a 35,000 sq. ft. cGMP facility with 500L bioreactor scale in downtown Oklahoma City, featuring a Charles River Laboratories-operated RightSourceSM on-site QC laboratory. Wheeler Bio has announced plans for a 52,000 sq. ft. large-scale manufacturing expansion adjacent to a biomanufacturing workforce training center in the OKC Innovation District. Its service offering is extended through strategic partnerships with Alloy Therapeutics (lead optimization), Pharmefex (regulatory), and Pyramid Pharma Services (fill-finish), enabling end-to-end discovery-to-IND program management under a single client interface.
Wheeler Bio generates revenue through project-based, fixed-fee CDMO contracts with emerging biopharma companies developing monoclonal antibodies, bispecifics/multispecifics, fusion proteins, and antibody-drug conjugates. The company has raised approximately $80M across Seed, Series A, and Series A-1 rounds between 2022 and 2025, with Echo Investment Capital and Alloy Therapeutics as consistent co-lead investors. As of late 2025, the company employs 51-100 people and is pursuing geographic expansion into Asia-Pacific through a strategic partnership with Mitsubishi Corporation.
Wheeler Bio firmographics
Firmographics- Name
- Wheeler Bio
- Legal name
- Wheeler Bio, Inc.
- Website
- https://wheelerbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Wheeler Bio is a privately held biologics CDMO that provides antibody-based therapeutic development and cGMP manufacturing services for emerging biopharma clients. Its ModularCMC platform delivers phase-appropriate, fixed-fee work packages compressing gene-to-clinic timelines to as few as 10 months.
- Ownership category
- akta.pro rank
Wheeler Bio industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Wheeler Bio is headquartered
LocationHeadquarters
- HQ city
- Oklahoma City
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Wheeler Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- CDMO Development and Manufacturing Services: Wheeler Bio generates revenue through contract development and manufacturing services for antibody-based therapeutics. Services span cell line development, process and analytical development, non-cGMP and cGMP drug substance manufacturing, drug product manufacturing, and regulatory CMC support. Revenue is project-based with fixed-fee work packages and milestone-based billing.
- Partnered Service Fees: Fees from integrated partner services including regulatory support (Pharmefex), fill-finish (Pyramid Pharma Services), and lead optimization (Alloy Therapeutics), where Wheeler coordinates and manages delivery as the primary client interface.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CDMO project pricing — Lead Selection module |
| Other | Multi-year contract | Custom CDMO project pricing — Cell Line Development module |
| Other | Multi-year contract | Custom CDMO project pricing — Lead to Clinic module |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Wheeler Bio product offering
Product offeringCore offering
Wheeler Bio is a biologics contract development and manufacturing organization (CDMO) that provides antibody-based therapeutic development and manufacturing services through its proprietary ModularCMC platform. Services span cell line development, process and analytical development, formulation, master cell banking, non-GMP and cGMP drug substance manufacturing, drug product manufacturing, and integrated regulatory CMC support for emerging biopharma clients.
Product overview
Wheeler Bio is a biologics CDMO (contract development and manufacturing organization) offering a platform-plus-modules architecture centered on its ModularCMC™ platform. ModularCMC™ provides structured, phase-appropriate work packages for antibody-based therapeutics development from discovery through CGMP manufacturing. The platform includes three integrated service modules (Lead Selection, Clone Selection, CDMO Selection) composed of 10 discrete work packages covering stable pool generation, process/analytical/formulation development, single cell cloning, cell banking, drug substance manufacturing, drug product management, and regulatory documentation. Complementary service modules include Cell Line Development, Process Development & Optimization, Analytical Development & Qualification, and Formulation Development. Manufacturing services encompass Master Cell Banking, Drug Substance Manufacturing, and Drug Product Manufacturing. Partnered services extend capabilities through alliances with Alloy Therapeutics (lead optimization), Pharmefex (regulatory support), and Pyramid Pharma Services (fill-finish). The company specializes in therapeutic modalities including monoclonal antibodies (mAbs), multispecifics, fusion proteins, and antibody-drug conjugates (ADCs).
Differentiator
Problem solved
Functional benefit
Brands
- Portable CMC™: Open-source CMC middleware platform that delivers speed, efficiency, predictability, and freedom to operate by integrating discovery CROs and CDMOs to bridge the translational gap from discovery to IND filing
- ModularCMC™
Products and services
- ModularCMC A mammalian cell culture-based modular CMC platform for antibody-based therapeutic development that provides structured, phase-appropriate work packages using Quality-by-Design principles, AI/ML-enabled clone selection, and data-driven analytics to derisk development and reduce timelines from discovery to cGMP manufacturing.
- Cell Line Development Mammalian cell line development services combining advanced expression technologies including Leap-In Transposase with experienced teams integrated into the ModularCMC platform to accelerate the path from discovery to cGMP manufacturing for antibody-based therapeutics.
- Lead Selection Program Non-clonal cell line development program providing transfection to top pool selection in as few as 3 months; generates representative materials, early product quality assessments, and manufacturability data for early-stage antibody programs.
- Cell Line Development Program Clonal cell line development program providing transfection to MCB conditional release in as few as 6 months using state-of-the-art expression technologies and automated workflows.
- Rapid Tox Supply Program providing transfection to SBC-derived toxicology material supply in as few as 3 months for IND-enabling studies.
- Traditional Tox Supply Program providing transfection to clonally-derived toxicology material supply in as few as 6 months for IND-enabling studies.
- Lead to Clinic Program Complete program integrating all ModularCMC work packages from transfection to drug product release in as few as 10 months.
- Process Development & Optimization Data-driven upstream and downstream process development services including seed train optimization, media screening, bioreactor optimization, and purification development to ensure high yield, consistent quality, and efficient scale-up for antibody therapeutics.
- Analytical Development & Qualification Molecular characterization and phase-appropriate analytical methods designed to deliver IND/CTD-ready insights including structural analysis, potency assays, method qualification, and stability studies for antibody-based therapeutics.
- Formulation Development Stage-appropriate formulation development customized to the molecule's target product profile, ranging from platform screening for standard monoclonal antibody programs to bespoke development for complex antibody formats.
- Master Cell Banking cGMP cell banking services establishing well-characterized production cell banks to support reliable biologics manufacturing and clinical drug substance supply.
- Drug Substance Manufacturing Integrated drug substance manufacturing for antibody therapeutics, providing non-GMP and cGMP production at 500L scale with high-quality, fully traceable material.
- Drug Product Manufacturing Drug product services from cGMP drug substance release through fill-finish coordination, drug product release testing, and ICH Q1A(R3)-aligned stability studies.
- Lead Optimization (Partnered with Alloy Therapeutics) Partnered service combining Alloy Therapeutics' antibody discovery platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach for a seamless path from discovery to clinical manufacturing.
- IND Regulatory Support (Partnered with Pharmefex) Partnered regulatory service providing integrated IND and regulatory CMC support including CTD Module 3 authoring, submission strategy, and regulatory execution from early development through IND filing.
- Fill-Finish (Partnered with Pyramid Pharma Services) Partnered fill-finish service providing vial, syringe, and cartridge filling for liquid and lyophilized products at clinical to commercial scales, with Wheeler Bio providing High-Touch project management throughout.
- Multispecifics Development Integrated, phase-appropriate development and manufacturing support for bispecific and multispecific antibody therapeutics, addressing expression, stability, and product quality considerations.
- ADC Manufacturing Antibody-drug conjugate development and manufacturing support including antibody expertise, process development, and analytical characterization aligned with downstream conjugation and manufacturability requirements.
- mAbs Manufacturing & Development Monoclonal antibody therapeutics manufacturing and development services for emerging biopharma clients using mammalian CHO cell-based production.
- Fusion Proteins Manufacturing & Development Fc fusion protein therapeutics manufacturing and development services using mammalian cell-based production systems.
Quantifiable outcome
- Gene to clinic in as few as 10 months (transfection to Drug Product release)
- +4 more outcomes
Companies that use Wheeler Bio
Customer profileSegments2 records
Ideal customer profiles2 records
Wheeler Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Wheeler Bio partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered strategic, core and flagship.
- University of OklahomastrategicResearchers at OU led by Professor Chongle Pan developed a machine learning model in collaboration with Wheeler Bio that predicts high-yield cell lines for monoclonal antibody production with 76.2% accuracy. The model uses the Luedeking-Piret equation to analyze early-stage growth data, addressing a weeks-long bottleneck in the biomanufacturing process. Research was funded by a $35M U.S. EDA program for Oklahoma City's biotechnology sector.
- Charles River LaboratoriescoreCharles River Laboratories operates an on-site RightSourceSM biologics testing laboratory at Wheeler Bio's Oklahoma City cGMP facility. Charles River provides and operates all QC testing infrastructure using their quality management systems, test methods, and SOPs. The RightSourceSM lab began operations in Q3 2023 and started in-process and release testing by Q4 2023.
- ATUMcoreWheeler Bio licensed ATUM's proprietary Leap-In Transposase and miCHO cell line development technology to incorporate into its cell line development platform. The technology enables semi-targeted gene insertion for highly productive, stable CHO cell lines with an established regulatory track record and rapid speed-to-clinic workflow.
- Alloy TherapeuticsflagshipAlloy Therapeutics, a Boston-based biotechnology company providing antibody discovery platforms, partnered with Wheeler Bio at founding to create a seamless path from antibody discovery to clinical manufacturing. The partnership combines Alloy's transgenic mouse platforms and lead optimization expertise with Wheeler Bio's ModularCMC approach, providing integrated project management from discovery through manufacturing. Alloy is both a founding strategic partner and an investor in Wheeler Bio.
- PharmefexcoreWheeler Bio partners with Pharmefex for integrated IND regulatory support, combining deep regulatory expertise with ModularCMC platform data. Services include CTD Module 3 documentation, submission strategy, regulatory execution from early development through IND filing. Pharmefex brings 11 years of experience, 33 consultants, and 5 regulatory approvals.
- Pyramid Pharma ServicescoreWheeler Bio partners with Pyramid Pharma Services for seamless fill-finish services including vial, syringe, and cartridge filling; liquid and lyophilized products; and packaging and assembly. Wheeler Bio provides High-Touch project management throughout the fill-finish process, enabling seamless transition from drug substance manufacturing without technology transfer delays.
Scale indicators8 records
Recent moves11 records
Expansion highlights5 records
Wheeler Bio competitors and assessment
Company assessmentDirect peers
- KBI Biopharma: Mid-sized biologics CDMO focused on mammalian cell line development, process development, and cGMP manufacturing for clinical-stage programs. Direct peer of Wheeler on antibody CDMO services targeting emerging biopharma with similar scale and modality focus.
- Resilience: U.S.-headquartered biologics CDMO with manufacturing across multiple modalities including antibodies and vaccines, targeting similar emerging biopharma customers. Comparable to Wheeler on mammalian antibody CDMO offerings at overlapping scales.
- Cytovance Biologics: Oklahoma City-based biologics CDMO offering mammalian cell culture, microbial, and plasmid DNA manufacturing services. Direct geographic and modality peer to Wheeler, with a longer operating history and broader modality mix including microbial biologics.
- Bionova Scientific: U.S.-based biologics CDMO providing mammalian cell line development, process development, and GMP manufacturing services for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused CHO antibody CDMO services at similar scale.
Broad incumbents
- WuXi Biologics: One of the largest biologics CDMOs globally, offering end-to-end antibody discovery-to-commercial services with extensive CHO-based capacity. Direct competitor for Wheeler on antibody CDMO work but with substantially greater scale, though recent U.S. regulatory headwinds may shift competitive dynamics.
- Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO with mammalian and microbial capabilities across clinical and commercial scales, frequently competing for emerging biopharma programs. Comparable to Wheeler on antibody CDMO services but with significantly larger infrastructure and longer operating history.
- Samsung Biologics: Global biologics CDMO with very large-scale mammalian manufacturing capacity, increasingly focused on emerging biotech CDMO services. Comparable to Wheeler on CHO antibody CDMO offerings but with multi-fold greater bioreactor scale and capacity.
- AGC Biologics: Global biologics CDMO offering mammalian and microbial development and manufacturing services for clinical and commercial supply. Comparable to Wheeler on antibody-focused mammalian CDMO services, with broader modality coverage and larger footprint.
- Lonza Biologics: One of the world's largest biologics CDMOs offering mammalian cell culture development and manufacturing across scales, with global facilities and broad modality coverage. Directly comparable to Wheeler on CHO-based antibody manufacturing but at vastly greater scale and commercial-supply reach.
Emerging players
- Stellar Biologics: Smaller emerging biologics CDMO focused on mammalian cell line development and clinical-stage manufacturing for antibody therapeutics. Comparable to Wheeler on emerging-biopharma-focused antibody CDMO positioning with similar scale.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Wheeler Bio social profiles
Digital presenceWheeler Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wheeler Bio leadership team
Management profileNumber of profiles
Profiles19 records
Wheeler Bio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wheeler Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wheeler Bio
What does Wheeler Bio do?
Wheeler Bio is a biologics contract development and manufacturing organization (CDMO) that provides antibody-based therapeutic development and manufacturing services through its proprietary ModularCMC platform. Services span cell line development, process and analytical development, formulation, master cell banking, non-GMP and cGMP drug substance manufacturing, drug product manufacturing, and integrated regulatory CMC support for emerging biopharma clients.
Is Wheeler Bio a public or private company?
Wheeler Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Wheeler Bio founded?
Wheeler Bio was founded in 2021. It employs 51 to 100 people.
Where is Wheeler Bio based?
Wheeler Bio is headquartered in Oklahoma City, United States, in the North America region.
How does Wheeler Bio make money?
Two revenue lines are on record. CDMO Development and Manufacturing Services are the primary driver. The others are partnered Service Fees.
Who are Wheeler Bio's main competitors?
Direct peers on record are KBI Biopharma, Resilience, Cytovance Biologics and Bionova Scientific. Broad incumbents are WuXi Biologics, Fujifilm Diosynth Biotechnologies, Samsung Biologics, AGC Biologics and Lonza Biologics. Stellar Biologics is listed as an emerging player.
Does Wheeler Bio have an API?
No public API is recorded for Wheeler Bio.
What industry is Wheeler Bio in?
Wheeler Bio's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2834.